Pharmacology and Toxicology

Bulletin of Experimental Biology and Medicine

, Volume 157, Issue 3, pp 344-349

First online:

Noopept Normalizes Parameters of the Incretin System in Rats with Experimental Diabetes

  • R. U. OstrovskayaAffiliated withV. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences Email author 
  • , N. N. ZolotovAffiliated withV. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences
  • , I. V. OzerovaAffiliated withV. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences
  • , E. A. IvanovaAffiliated withV. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences
  • , I. G. KapitsaAffiliated withV. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences
  • , K. V. TarabanAffiliated withV. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences
  • , A. M. MichunskayaAffiliated withV. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences
  • , T. A. VoroninaAffiliated withV. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences
  • , T. A. GudashevaAffiliated withV. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences
    • , S. B. SeredeninAffiliated withV. V. Zakusov Research Institute of Pharmacology, the Russian Academy of Medical Sciences

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Experiments on adult Wistar rats with streptozotocin-induced diabetes showed that antihyperglycemic activity of an original nootropic and neuroprotective drug Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is more pronounced under conditions of oral application than after intraperitoneal injection. These data provided a basis for studying the effect of Noopept on major indexes of the incretin system. Streptozotocin was shown to decrease the concentrations of incretin GLP-1 and insulin in the blood. Noopept had a normalizing effect on these parameters. This influence of Noopept was not related to the inhibition of a major enzyme metabolizing incretins (dipeptidyl peptidase IV). A reference drug sitagliptin also increased the contents of incretins and insulin, which was associated with the inhibition of dipeptidyl peptidase IV. It is known that GLP-1 increases NGF expression in the insular system. Our results suggest that the increase in incretin activity contributes to the antiapoptotic effect of Noopept on pancreatic β cells. The mechanism for an increase in blood GLP-1 level after oral application of Noopept requires further investigations.

Key Words

diabetes Noopept sitagliptin NGF glucagon-like peptide-1